Skip to main content
GlaxoSmithkline Pharmaceuticals Ltd. logo

GlaxoSmithkline Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · GLAXO ISIN · INE159A01016 LEI · 3358002TNSC1U2DWNY52 BSE.NS Manufacturing
Open in API
Filings indexed 1,604 across all filing types
Latest filing 2026-05-18 Call Transcript
Country IN India
Listing BSE.NS GLAXO

About GlaxoSmithkline Pharmaceuticals Ltd.

https://india-pharma.gsk.com/en-in/home/

GlaxoSmithkline Pharmaceuticals Ltd. is a research-based organization specializing in the development, manufacture, and commercialization of prescription medicines and vaccines. The company’s portfolio spans multiple therapeutic areas, including anti-infectives, dermatology, gynecology, oncology, and respiratory health. Key products include Augmentin, Calpol, Ceftum, and Eltroxin. It maintains a significant presence in the vaccines sector, offering protection against diseases such as pneumococcal infection, hepatitis, and varicella. By integrating global research and development expertise, the entity focuses on delivering innovative treatments and improving patient outcomes. Its operations are supported by a robust supply chain and distribution infrastructure designed to provide broad access to essential medical products.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 87% confidence The document includes the full text transcript of GlaxoSmithKline Pharmaceuticals Limited’s Q4 FY2026 and full year earnings conference call, complete with moderator introduction, management discussion, financial details, and Q&A setup. This matches the definition of a Call Transcript.
2026-05-18 English
As per attachment
Call Transcript Classification · 92% confidence The document is a full transcript of the Q4 FY2026 and Full Year Earnings Call for GlaxoSmithKline Pharmaceuticals Limited, complete with moderator introduction, management and CFO remarks, slide references, and Q&A preparation. This matches the definition of a Call Transcript (CT) rather than an earnings release summary or report publication announcement.
2026-05-18 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The document is a letter from GlaxoSmithKline Pharmaceuticals Limited to the BSE and NSE dated May 14, 2026, stating that the company has published advertisements in newspapers relating to the audited financial results for the quarter and year ended March 31, 2026, and enclosing the public notice (advertisement) as required under the Listing Obligations. The document does not contain actual financial statements or data itself but simply notifies the exchanges of the publication of the results. Under the “menu vs. meal” rule, this is a Report Publication Announcement, not the report itself.
2026-05-14 English
As per attachment
Report Publication Announcement Classification · 89% confidence The document is a letter from GlaxoSmithKline to the Bombay Stock Exchange and National Stock Exchange enclosing newspaper advertisements for its audited financial results (quarter & year ended 31 March 2026). It does not present actual financial statements but rather announces and attaches publication of those results in newspapers. Under the “Menu vs Meal” rule, this is an announcement of report publication rather than the report itself. Therefore, it should be classified as a Report Publication Announcement (RPA).
2026-05-14 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 82% confidence The submission is a mandatory stock exchange disclosure under SEBI listing rules (Regulation 30) announcing the outcome of analyst/institutional investor meetings and providing a link to the recording. It does not itself contain a financial report or presentation content and is an exchange filing under regulatory obligations. Therefore it falls into the general Regulatory Filings category.
2026-05-13 English
As per attachment
Regulatory Filings Classification · 88% confidence The document is a notification to stock exchanges under SEBI LODR Regulation 30 regarding the outcome of analyst/institutional investor meeting schedules and provides a link to uploaded recordings. It contains no financial statements, no detailed report, and is purely a regulatory disclosure rather than a report itself. It does not fit any specific category (earnings release, call transcript, capital update, etc.), so it defaults to a general regulatory announcement.
2026-05-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.